A recent clinical trial has shown that nerandomilast, a treatment developed by Boehringer Ingelheim, is effective in slowing the progression of lung function decline in patients with progressive pulmonary fibrosis over the course of one year.
The study, conducted under the FIBRONEER-ILD trial (ClinicalTrials.gov number NCT05321082), included participants diagnosed with progressive fibrosing interstitial lung diseases (ILDs). The primary endpoint measured was the change in forced vital capacity (FVC), a critical indicator of lung function in patients with chronic lung conditions.
After 52 weeks of treatment, patients receiving nerandomilast exhibited a significantly smaller decline in FVC compared to those given a placebo. This suggests that nerandomilast may provide a clinical benefit by slowing the deterioration of pulmonary function, a key concern in the management of progressive pulmonary fibrosis.
The findings mark a notable advancement in the therapeutic options available for individuals suffering from this debilitating group of lung diseases. Progressive pulmonary fibrosis is characterized by worsening respiratory symptoms and declining lung capacity, often leading to severe disability or death. Treatments that can slow or modify the course of the disease are highly sought after.
The study was funded by Boehringer Ingelheim and represents part of a comprehensive research effort to develop novel therapies for fibrosing lung diseases. Further details, including the specific magnitude of FVC preservation and safety outcomes, are expected in full peer-reviewed publications.
This development may pave the way for additional clinical evaluation and potential regulatory approval of nerandomilast as a new standard of care in the treatment of progressive fibrosing ILDs.
Source: https:// – Courtesy of the original publisher.
